This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.
Patients and baseline variables will be captured retrospectively, but outcome measures will be prospectively ascertained.
Study Type
OBSERVATIONAL
Enrollment
1,000
No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
Regeneron Research Facility
Tarrytown, New York, United States
Real-world response rate (rwRR)
Time frame: Approximately 3 years
Any treatment-emergent immune-mediated adverse event (imAE)
Time frame: Approximately 3 years
Any treatment-emergent imAE resulting in hospitalization
Time frame: Approximately 3 years
Any treatment-emergent imAE resulting in death
Time frame: Approximately 3 years
Specific treatment-emergent imAEs
Time frame: Approximately 3 years
Real-world duration of response (rwDOR)
Time frame: Approximately 3 years
Real-world progression-free survival (rwPFS)
Time frame: Approximately 3 years
Real-world overall survival (rwOS)
Time frame: Approximately 3 years
Treatment-emergent immune-mediated adverse events (imAEs)
Time frame: Approximately 3 years
Infusion-related reaction (IRR)
Time frame: Approximately 3 years
IRR resulting in hospitalization
Time frame: Approximately 3 years
IRR resulting in death
Time frame: Approximately 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.